Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

Fig. 2

Progression-free survival and overall survival according to median pTKa levels: a PFS according to Baseline pTKa (cutoff 292 Du/L). b OS according to Baseline pTKa. c PFS according to 4 weeks pTKa (cutoff 134 Du/L). d OS according to 4 weeks pTKa. e PFS according to pTKa level changes between baseline and 4 weeks. f OS according to pTKa level changes between baseline and 4 weeks

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us